We are live on ! Find out more
BBIO icon

BridgeBio Pharma
BBIO

88 hedge funds and large institutions have $3.67B invested in BridgeBio Pharma in 2019 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 31 increasing their positions, 16 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

190% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 10

94% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 16

65% more capital invested

Capital invested by funds: $2.22B → $3.67B (+$1.45B)

40% more funds holding in top 10

Funds holding in top 10: 5 → 7 (+2)

17% more funds holding

Funds holding: 75 → 88 (+13)

1.71% less ownership

Funds ownership: 88.47% → 86.77% (-1.7%)

Holders
88
Holders Change
+13
Holders Change %
+17.33%
% of All Funds
1.73%
Holding in Top 10
7
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+40%
% of All Funds
0.14%
New
29
Increased
31
Reduced
16
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$74.5M
2
BlackRock
BlackRock
New York
+$32.8M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$15.2M
4
State Street
State Street
Massachusetts
+$12.7M
5
N
Nuveen
North Carolina
+$12.4M

Top Sellers

Rank Fund Capital Flow
1
Victory Capital Management
Victory Capital Management
Texas
-$19.7M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$12.3M
3
SM
SCGE Management
California
-$8.93M
4
DM
Deerfield Management
New York
-$6.23M
5
CAM
Cormorant Asset Management
Massachusetts
-$2.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
Ensign Peak Advisors
26
Ensign Peak Advisors
Utah
$3.87M +$3.06M +110,425 New
FIM
27
Fernwood Investment Management
Massachusetts
$3.66M +$255K +9,200 +10%
Victory Capital Management
28
Victory Capital Management
Texas
$3.17M -$19.7M -711,699 -89%
Allianz Asset Management
29
Allianz Asset Management
Germany
$2.84M +$2.25M +81,096 New
Bank of New York Mellon
30
Bank of New York Mellon
New York
$2.79M +$534K +19,265 +32%
GPP
31
Great Point Partners
Connecticut
$2.75M +$2.17M +78,400 New
UBS AM
32
UBS AM
Illinois
$2.69M -$6.02K -217 -0.3%
EAM
33
Erste Asset Management
Austria
$2.1M +$943K +34,000 +148%
Bank of America
34
Bank of America
North Carolina
$1.4M +$973K +35,086 +721%
TCM
35
Tekla Capital Management
Massachusetts
$1.38M +$1.09M +39,228 New
Morgan Stanley
36
Morgan Stanley
New York
$1.34M +$823K +29,682 +346%
California Public Employees Retirement System
37
California Public Employees Retirement System
California
$1.31M +$1.04M +37,515 New
AC
38
Athanor Capital
New York
$1.24M -$46.2K -1,665 -5%
California State Teachers Retirement System (CalSTRS)
39
California State Teachers Retirement System (CalSTRS)
California
$1.21M -$19.3K -697 -2%
GC
40
Grace Capital
Massachusetts
$1.21M +$305K +11,000 +47%
State of Wisconsin Investment Board
41
State of Wisconsin Investment Board
Wisconsin
$1.2M – – –
ProShare Advisors
42
ProShare Advisors
Maryland
$1.04M +$826K +29,786 New
Ameriprise
43
Ameriprise
Minnesota
$1.02M +$39.6K +1,429 +5%
ACM
44
Atika Capital Management
New York
$991K +$785K +28,300 New
RhumbLine Advisers
45
RhumbLine Advisers
Massachusetts
$989K +$102K +3,696 +15%
AllianceBernstein
46
AllianceBernstein
Tennessee
$962K +$761K +27,453 New
Barclays
47
Barclays
United Kingdom
$916K +$345K +12,431 +91%
Citigroup
48
Citigroup
New York
$874K +$664K +23,959 +2,386%
CS
49
Credit Suisse
Switzerland
$780K +$616K +22,232 New
New York State Common Retirement Fund
50
New York State Common Retirement Fund
New York
$701K +$63.8K +2,300 +13%
1
2
3 4

BBIO Hedge Fund Activity: Q4 2019 in Review

88 of the 5,076 institutional investors tracked by Wall St. Rank reported a position in BridgeBio Pharma (BBIO) for Q4 2019, worth a combined $3.67B — up 65% from $2.22B a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new BBIO positions and 10 closed out — a net gain of 19 holders — while 31 added to existing stakes and 16 trimmed.

The largest buyer was Janus Henderson Group, adding an estimated $74.5M. The largest seller was Victory Capital Management, cutting an estimated $19.7M.

  • 88 institutional investors held BridgeBio Pharma (BBIO) as of Q4 2019, up from 75 in Q3 2019.
  • Funds reported $3.67B of BridgeBio Pharma stock for Q4 2019, up 65% quarter-over-quarter.
  • 29 funds opened new BridgeBio Pharma positions in Q4 2019 and 10 closed out, a net change of +19 holders.
  • The largest BridgeBio Pharma buyer in Q4 2019 was Janus Henderson Group, an estimated $74.5M added.
  • The largest BridgeBio Pharma seller in Q4 2019 was Victory Capital Management, an estimated $19.7M sold.

Based on aggregated 13F filings for Q4 2019.